Interindividual differences in response to pharmacological treatment are a major health concern. Importantly, only 50%–75% of patients have been shown to react adequately to common pharmacological interventions, whereas the others exhibit either a lack of efficacy or suffer from adverse drug reactions (ADRs).
ref: Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics. Trends Mol. Med. 2001;7:201–204. doi: 10.1016/S1471-4914(01)01986-4.
Meet Dynamic PGx
Converting a potentially dangerous guess into a genetically-informed decision.
Reducing your clinical, financial and legal risks as
the adoption of pharmacogenomics and precision medicine becomes the standard of care.
We now have advanced genetic tools that provide insight into the individualized drug response for each patient. The challenge in utilizing these advanced genetic tools is that genetic science is complicated, and the volume of information typically provided by current standard pharmacogenomic reports is large. Deciphering the results is a time-consuming and daunting task for the medical practitioner. It is so daunting, in fact, that the information is not utilized. It is simply too much information.
Dynamic PGx is the solution that provides physicians and pharmacists a better roadmap on how to best access each patient on a personalized level, increasing the likelihood of reaching a therapeutic goal and decreasing the risk of an Adverse Drug Reaction (ADR).
Dynamic PGx In Real-Time
The information is out there, we just need to let it in!
Dynamic PGx provides specific, actionable information regarding the possible interactions of the 400 most-prescribed medications both between themselves and with the CYPs that metabolize these substances in the human body.
Medication Detail Overload
The details surrounding any one medication are massive. The details surrounding all of the medications, along with their various interactions with one another, that a physician typically must recall in a single day of attending patients are enormous. The human mind simply cannot recall all of these details for all possible medications. The Rx Factor medication database provides at the user’s fingertips drug descriptions, indication for use, time-to-peak, toxic presentation and virtually all other essential information of all commonly-prescribed medications.
Dynamic PGx analysis includes over-the-counter medications/CYP interaction which can still carry a risk, even though they do not require a prescription. The possibility exists of an ADR from drug interactions, side effects or harm due to excessive doses.
One barrier to the implementation of pharmacogenomic testing in real life is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for a drug in question. Peer-reviewed guidelines are published and designed to help clinicians understand how genetic test results should be used to optimize drug therapy. When the information exists, the appropriate PGx (Drug/Gene Interface) is provided. PGx-based drug dosing guidelines are published by such recognized institutions as Stanford’s PharmGKB (CPIC), the Royal Dutch Association (DPWG) and the Canadian Pharmacogenomics Network (CPNDS) and other professional societies. The Rx Factor detects aberrant variants and automatically provides guideline information when available for the user to review.
Dynamic PGx dynamically analyzes intra-protocol relationships (new drug/CYP/existing protocol) for inhibitor/inducer compromise. Inhibitors block the metabolic activity of one or more CYP enzymes. Inducers, on the other hand, increase CYP enzyme activity by increasing enzyme synthesis. Metabolic inhibition or induction has a probability of impacting enzyme activity resulting in expression different than test genotype/phenotype results.
Environment: the complex of physical, chemical and biotic factors that act upon an organism and ultimately determine its form and survival. Prescription medications, over-the-counter meds, foods, nutrients, herbals and many other substances create an environment with the respective CYPs being the point of focus. Inhibitors and inducers represent influences that must be considered given a patient's specific protocol. These influencers can be in an existing protocol or introduced as part of new drug influence. Managing the removal of these compromising agents in a protocol are provided in PGX-managed strategies. The software recognizes these conflicts and provides "how-to" procedures thus avoiding such complications as phenoconversion.